Reference

Medical composition containing enalapril, benazepril or sotalol for preventing, treating and delaying hypertension and diseases and/or target organs damage

All Rights Reserved. Medical composition containing enalapril, benazepril or sotalol for preventing, treating and delaying hypertension and diseases and/or target organs damage. Chen, Guangliang; Wang, Linlin; Duan, Yanyan; Li, Li; Xu, Xiping (Anhui Provincial Institute of Biomedicine, Peop. Rep. China). Faming Zhuanli Shenqing Gongkai Shuomingshu CN 1891222 A 10 Jan 2007, 19pp. (Chinese). (People's Republic of China).In this article, certain chemicals are used. Some of their cas registry numbers are 86541-74-4 and 959-24-0 CODEN: CNXXEV. APPLICATION: CN 2010-81670 6 Jul 2005. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 The medical compn. contains: (1) one of enalapril, benazepril, or their active metabolites, medical precursor, and medical salts 5-40 mg, (2) one of sotalol, its active metabolites, medical precursor, or medical salts 5-40 mg, and (3) pharmaceutically acceptable carrier or excipient. The compn. can be tablet, sustained-release tablet, capsule or granule. The compn. can be used to prep. medicine for preventing, treating and delaying hypertension and interrelated diseases and/or target organs damage caused by hypertension, such as left ventricular hypertrophy, angina pectoris, myocardial infarction, etc. .

Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome

Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome. Fong, Benson M.; Cornett, Glen V. (Cotherix, Inc., USA). PCT Int. Appl. WO 2005009446 A1 3 Feb 2005, 48 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. 86541-74-4 and 62571-86-2 are also in the experiment. CLASS: ICM: A61K031-70. ICS: A61K031-44; A61K031-215; A61K031-19. APPLICATION: WO 2004-US23004 16 Jul 2004. PRIORITY: US 2003-2003/PV488040 17 Jul 2003. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 63 Preferred embodiments of the invention are related to novel therapeutic drug combinations and methods for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the invention are related to using a combination of cicletanine and a second antihypertensive agent (preferably a calcium antagonist, an ACE inhibitor, or an angiotensin II receptor antagonist) for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. .